- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 15- Assessing the Factors at Increased Risk for Cardiometabolic Events
When assessing what population is at an increased risk for developing a cardiometabolic event, Kenneth L. Schaecher, MD, FACP, CPC, explains that the patient who is disengaged is at the greatest risk. Dr Schaecher states that patients who do not make lifestyle changes and patients who are not adherent to their medicines are examples of disengaged patients.
Furthermore, the panelists discuss the cardiometabolic conditions that result in the greatest costs to managed care facilities. Dr Schaecher explains that diabetes is number 1.
Yehuda Handelsman, MD, FACP, FACE, FNLA, explains that while commonly overlooked, kidney disease is also a component of cardiovascular disease (CVD). Dr Handelsman believes that the outcomes of kidney disease pass beyond diabetes, but the condition is commonly overlooked because less patients present with kidney disease than diabetes.
Dr Schaecher concludes that patients need to have a better understanding of how kidney disease links to cardiometabolic events.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
